

Literatur

- Pezzani L, Milani, D (2020): Epidemiology of Neurofibromatosis Type 1. In: Tadini G, Legius E, Brems H (eds): Multidisciplinary Approach to Neurofibromatosis Type 1. Springer Nature, Switzerland, 1-4
- Denayer E, Legius E, Brems H (2020): Genetics and Pathway in Neurofibromatosis Type 1. In: Tadini G, Legius E, Brems H (eds): Multidisciplinary Approach to Neurofibromatosis Type 1. Springer Nature, Switzerland, 5-14
- National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987. Neurofibromatosis. 1988;1(3):172-8. PMID: 3152465.
- DeBella K, Szudek J, Friedman JM. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics. 2000 Mar;105(3 Pt 1):608-14. doi: 10.1542/peds.105.3.608. PMID: 10699117.
- Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, Blakeley J, Babovic-Vuksanovic D, Cunha KS, Ferner R, Fisher MJ, Friedman JM, Gutmann DH, Kehrer-Sawatzki H, Korf BR, Mautner VF, Peltonen S, Rauen KA, Riccardi V, Schorry E, Stemmer-Rachamimov A, Stevenson DA, Tadini G, Ullrich NJ, Viskochil D, Wimmer K, Yohay K; International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NFDC); Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021 Aug;23(8):1506-1513.
- Ortonne N, Wolkenstein P, Blakeley JO et al. Cutaneous neurofibromas: Current clinical and pathologic issues. Neurology. 2018; 10(91) (2 Suppl 1):5-13
- Akshintala S, Baldwin A, Liewehr DJ, et al. Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions. Neuro Oncol 2020;22(9):1368-1378
- Nguyen R, Klue L, Fuensterer C, Kentsch M, Friedrich RE, Mautner VF. Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits. J Pediatr. 2011 Oct;159(4):652-5.e2. doi: 10.1016/j.jpeds.2011.04.008. Epub 2011 May 31. PMID: 21621223.
- Evans DG, Baser ME, McGaughan J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002 May;39(5):311-4. doi: 10.1136/jmg.39.5.311. PMID: 12011145; PMCID: PMC1735122.
- Azizi AA, Walker DA, Liu JF, Sehested A, Jaspan T, Pemp B, Simmons I, Ferner R, Grill J, Hargrave D, Driever PH, Evans DG, Opoche E; SIOPE NF1 OPG Nottingham, UK, Workshop 2014. NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat. Neuro Oncol. 2021 Jan 30;23(1):100-111. doi: 10.1093/neuonc/noaa153. PMID: 32628746; PMCID: PMC7850076.
- Eleftheriou F, Kolanczyk M, Schindeler A, Viskochil DH, Hock JM, Schorry EK, Crawford AH, Friedman JM, Little D, Peltonen J, Carey JC, Feldman D, Yu X, Armstrong L, Birch P, Kendler DL, Mundlos S, Yang FC, Agiostratidou G, Hunter-Schaedle K, Stevenson DA. Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am J Med Genet A. 2009 Oct;149A(10):2327-38. doi: 10.1002/ajmg.a.33045. PMID: 19764036.
- Lidzba K, Granström S, Lindenau J, Mautner VF. The adverse influence of attention-deficit disorder with or without hyperactivity on cognition in neurofibromatosis type 1. Dev Med Child Neurol. 2012 Oct;54(10):892-7. doi: 10.1111/j.1469-8749.2012.04377.x. Epub 2012 Aug 9. PMID: 22881119.
- Walsh KS, Wolters PL, Widemann BC, Del Castillo A, Sady MD, Inker T, Roderick MC, Martin S, Toledo-Tamula MA, Struempfer K, Paltin I, Collier V, Mullin K, Fisher MJ, Packer RJ. Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1. Neurol Genet. 2021 Aug 6;7(5):e616. doi: 10.1212/NXG.0000000000000616. PMID: 34377779; PMCID: PMC8351286.
- Lalancette E, Cantin É, Routhier MÈ, Mailloux C, Bertrand MC, Kiaei DS, Larouche V, Tabori U, Hawkins C, Ellezam B, Décarie JC, Théoret Y, Métras MÈ, McKeown T, Ospina LH, Vairy S, Ramaswamy V, Coltin H, Sultan S, Legault G, Bouffet É, Lafay-Cousin L, Hukin J, Erker C, Caru M, Dehaes M, Jabado N, Perreault S, Lippé S. Impact of trametinib on the neuropsychological profile of NF1 patients. J Neurooncol. 2024 May;167(3):447-454. doi: 10.1007/s11060-024-04624-3. Epub 2024 Mar 5. PMID: 38443693.
- Vaassen P; Rosenbaum, T. (2016) Nevus anemicus as additional diagnostic marker of neurofibromatosis type 1 in childhood. Neuropediatrics 47:190-193.
- Gross AM, Dombi E, Wolters PL, Baldwin A, Dufek A, Herrera K, Martin S, Derdak J, Heisey KS, Whitcomb PM, Steinberg SM, Venzon DJ, Fisher MJ, Kim A, Bornhorst M, Weiss BD, Blakeley JO, Smith MA, Widemann BC. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. Neuro Oncol. 2023 Oct 3;25(10):1883-1894. doi: 10.1093/neuonc/noad086. PMID: 37115514; PMCID: PMC10547508.
- Cacchione A, Fabozzi F, Carai A, Colafati GS, Baldo GD, Rossi S, Diana M, Megaro G, Milano GM, Macchiaioli M, Crocoli A, De Ioris MA, Boccuto L, Secco DE, Zama M, Agolini E, Tomà P, Mastronuzzi A. Safety and Efficacy of Mek Inhibitors in the Treatment of Plexiform Neurofibromas: A Retrospective Study. Cancer Control. 2023 Jan-Dec;30:10732748221144930. doi: 10.1177/10732748221144930. PMID: 36598023; PMCID: PMC9830579.
- Kim H, Yoon HM, Kim EK, Ra YS, Kim HW, Yum MS, Kim MJ, Baek JS, Sung YS, Lee SM, Lim HS, Lee BJ, Lim HT, Kim D, Yoon J, Bae H, Hwang S, Choi YH, Kim KA, Choi IH, Lee SW, Park SJ, Lee BH. Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma. Neuro Oncol. 2024 Dec 5;26(12):2352-2363. doi: 10.1093/neuonc/noae121. PMID: 38975694; PMCID: PMC11630552.
- Vaassen P, Dürr NR, Rosenbaum T (2024) MEK-Inhibitor-Therapie NF1-assoziiierter plexiformer Neurofibrome. Neuropaediatrie 23:122-130.
- Klesse LJ, Jordan JT, Radtke HB, Rosser T, Schorry E, Ullrich N, Viskochil D, Knight P, Plotkin SR, Yohay K. The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities. Oncologist. 2020 Jul;25(7):e1109-e1116. doi: 10.1634/theoncologist.2020-0069. Epub 2020 Apr 22. PMID: 32272491; PMCID: PMC7356675.
- Azizi AA, Hargrave D, Passos J, Wolkenstein P, Rosenbaum T, Santoro C, Rosenmayr V, Pletschko T, Ascierto PA, Hernández HS. Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas. Neurooncol Pract. 2024 Apr 27;11(5):515-531. doi: 10.1093/nop/npae038. PMID: 39279781; PMCID: PMC11398946.
- Manoharan N, Liu KX, Mueller S, Haas-Kogan DA, Bandopadhyay P. Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era. Neoplasia. 2023 Feb;36:100857. doi: 10.1016/j.neo.2022.100857. Epub 2022 Dec 24. PMID: 36566593; PMCID: PMC9803951.
- Perrin S, Protic S, Bretegnier V, Laurendeau I, de Lageneste OD, Panara N, Ruckebusch O, Luka M, Masson C, Maillard T, Couplier F, Pannier S, Wicart P, Hadj-Rabia S, Radomska KJ, Zarhrate M, Ménager M, Vidaud D, Topilko P, Parfait B, Colnot C. MEK-SHP2 inhibition prevents tibial pseudarthrosis caused by NF1 loss in Schwann cells and skeletal stem/progenitor cells. Sci Transl Med. 2024 Jun 26;16(753):eadj1597. doi: 10.1126/scitranslmed.adj1597.
- Borrie SC, Plasschaert E, Callaerts-Vegh Z, Yoshimura A, D'Hooge R, Elgersma Y, Kushner SA, Legius E, Brems H. MEK inhibition ameliorates social behavior phenotypes in a Spred1 knockout mouse model for RASopathy disorders. Mol Autism. 2021 Jul 26;12(1):53. doi: 10.1186/s13229-021-00458-2. PMID: 34311771; PMCID: PMC8314535.
- Barrière S, Faure-Contier C, Leblond P, Philippe M, des Portes V, Lion François L, de Bellescize J, Sabatier I. Antiseizure effect of MEK inhibitor in a child with neurofibromatosis type 1-Developmental and epileptic encephalopathy and optic pathway glioma. Epileptic Disord. 2024 Feb;26(1):133-138. doi: 10.1002/epd2.20180. Epub 2023 Nov 29. PMID: 37983638.
- Carton C, Evans DG, Blanco I, Friedrich RE, Ferner RE, Farschtschi S, Salvador H, Azizi AA, Mautner V, Röhl C, Peltonen S, Stivaros S, Legius E, Oostenbrink R; ERN GENTURIS NF1 Tumour Management Guideline Group. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. EclinicalMedicine. 2023 Jan 13;56:101818. doi: 10.1016/j.eclinm.2022.101818. PMID: 36684394; PMCID: PMC9845795.
- Farschtschi S, Vaassen P, Klue L, Hartung T, Salamon J, Rosenbaum T. Age-Adapted Diagnostic Evaluation and Treatment of Patients With Type 1 Neurofibromatosis in Germany. Dtsch Arztebl Int. 2025 Feb 21;(Forthcoming):arztebl.m2024.0257. doi: 10.3238/arztebl.m2024.0257. Epub ahead of print. PMID: 39773869.
- DiPaolo DP, Zimmerman RA, Rorke LB, Zackai EH, Bilaniuk LT, Yachnis AT. Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain. Radiology. 1995 Jun;195(3):721-4. doi: 10.1148/radiology.195.3.7754001. PMID: 7754001.
- Di Stasi M, Cocozza S, Buccino S, Paoletta C, Di Napoli L, D'Amico A, Melis D, Ugga L, Villano G, Ruocco M, Scala I, Brunetti A, Elefante A. The role of unidentified bright objects in the neurocognitive profile of neurofibromatosis type 1 children: a volumetric MRI analysis. Acta Neurol Belg. 2024 Feb;124(1):223-230. doi: 10.1007/s13760-023-02381-0. Epub 2023 Sep 21. PMID: 37733157; PMCID: PMC10874314.